2024-09-01 - Analysis Report
##  Pfizer Inc. (PFE) Stock Analysis: 

**Company Overview:** Pfizer is a multinational pharmaceutical corporation that develops and produces medicines and vaccines for a wide range of diseases.

**1. Performance vs. S&P 500:**

* **Cumulative Return:**  PFE: -26.27%, VOO (S&P 500): 89.66%
* **Relative Underperformance:** PFE has significantly underperformed the S&P 500, with a cumulative return difference of -115.93%. 
* **Relative Divergence:** Currently at -100.21, indicating PFE is significantly lagging the market, and its relative performance is currently positioned at the 1.33 percentile of its historical range. 

**2. Recent Price Movement:**

* **Closing Price:** $29.01
* **Moving Averages:**
    * 5-Day: $28.84
    * 20-Day: $28.85
    * 60-Day: $28.80

The stock price is trading slightly above its moving averages, indicating potential short-term upward pressure.

**3. Technical Indicators:**

* **RSI:** 60.69
* **PPO:** -0.02
* **Delta_Previous_Relative_Divergence:** -8.37

The RSI indicates a slightly overbought condition, while the PPO shows a slight downward trend. The negative Delta_Previous_Relative_Divergence suggests a recent decrease in relative strength compared to the market.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

Pfizer's recent earnings have exceeded expectations in the last two quarters, demonstrating resilience and strong performance. The most recent quarter (Q2 2024) saw an EPS of 0.6, exceeding the expected 0.458. 

**5. Overall Analysis:**

PFE has significantly underperformed the S&P 500 in the long term. While recent earnings have been strong, the stock currently displays some technical indicators suggesting potential short-term downward pressure. The relative divergence and recent decrease in relative strength compared to the market warrant further investigation.

**6. Summary in English:**

Pfizer Inc. (PFE) has experienced significant underperformance against the S&P 500, with a cumulative return difference of -115.93%. While the recent earnings have been positive and exceeded expectations, the current technical indicators suggest potential short-term downward pressure. The RSI is slightly overbought, the PPO is showing a slight downward trend, and the negative Delta_Previous_Relative_Divergence indicates a recent decrease in relative strength compared to the market. Investors should monitor these technical signals and consider the long-term underperformance before making any investment decisions. 
